Buy DXCM to the moon
heres the case for DXCM $DexCom (DXCM.US)$
Stock fell in June due to missed earnings, but likely competitors took opportunity to chum the press. Fundamentally Dexcom is a phenomenal company with the edge on the market as their products have patented tech (most accurate on the market). They have major contracts with large insulin pump providers and cell carriers. They have a follow app for family members to track their loved one’s glucose (think children with diabetes). It’s a critical need in a growing space. Vanguard and Blackrock upped their positions in DXCM. Quant rating 7.77 for quality; 7.66 for growth. Tremendous potental, preferred by physicians, best tech and reach. Excellent R&D with new OTC products. Recently price crossed moving avg (21 day). High Volume. Released Silo product today. Among diabetic community, Dexcom is most trusted. Its a no brainer, fire sale. Expecting 30% upside by Dec 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
我勒个去 : It has been falling for 4 consecutive days, sigh.
tkhan : also facing tough competition from abbievie
joe black8 : Bunch of crap, this company is not vital if it dissapears tomorrow, noone would miss it